Top of page
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content

Associate Professor Elin Gray

Associate Professor

Contact Information Telephone: +61 8 6304 2756, Mobile: 0406840197, Email:, Campus: Joondalup, Room: JO17.309
Staff Member Details
Telephone: +61 8 6304 2756
Mobile: 0406840197
Campus: Joondalup  
Room: JO17.309  


Elin is a Postdoctoral Research Fellow in Melanoma within the School of Medical and Health Sciences.


Associate Professor Elin Gray is a Cancer Research Trust Postdoctoral Fellow and Senior Researcher at the Melanoma Research Group, within the School of Medical and Health Sciences at ECU. Prior to appointment at ECU, Elin worked at the National Institute for Communicable Diseases in South Africa; the Vaccine Research Center at the NIH, USA and the Duke Human Vaccine Institute, Duke University, USA. Elin’s previous research focused in immunology and virology before relocating to Edith Cowan University in 2011. Associate Professor Gray's current research aims to identify blood biomarkers for diagnosis of melanoma and to guide treatment decisions. Her team utilises and develops novel genetic analysis methodologies to interrogate biomarkers such as circulating tumour cells, circulating tumour DNA and exosomes, to provide information on the tumour evolution and cancer development. In addition, Elin is interested in identifying mechanisms of drug resistance and developing better treatment strategies. Associate Professor Gray works in close collaboration with leading oncologists and pathologists to translate these results into clinical application.


  • Doctor of Philosophy, South Africa, 2008.
  • Master in Biochemistry, Cuba, 2001.
  • Bachelor of Biochemistry, Cuba, 1997.


Recent Research Grants

  • ACRF Centre for Advanced Cancer Genomics,  Australian Cancer Research Foundation,  Cancer Research Grants,  2019 - 2026,  $2,377,000.
  • Enabling Advanced Single Cell Cancer Genomics in Western Australia,  Cancer Research Trust,  The Grant,  2017 - 2022,  $305,925.
  • Developing blood tests to guide treatment of melanoma,  Cancer Council of WA Inc,  Fellowship,  2019 - 2022,  $955,724.
  • Circulating tumour DNA as a biomarker of treatment response for patients with advanced high grade serous ovarian cancer receiving neoadjuvant chemotherapy with and without durvalumab and tremilimumab as part of the iprime study,  Australia New Zealand Gynaecological Oncology Group (ANZGOG),  Grant,  2019 - 2021,  $49,317.
  • Early Detection of Cancer Spread and Treatment of Ocular Melanoma,  Cancer Council of WA Inc,  PhD Top Up Scholarship,  2018 - 2020,  $30,000.
  • Medical and Health Research Infrastructure Fund 2018 (Round 22),  Department of Health WA,  Medical and Health Research Infrastructure,  2019 - 2020,  $20,979.
  • Liquid biopsy for personalised monitoring of melanoma patients ,  National Health and Medical Research Council,  Development Grants,  2017 - 2020,  $950,389.
  • Translation of "Liquid Biopsy" Research into Clinical Practice,  Western Australian Health Translation Network,  Early Career Fellowships,  2019 - 2020,  $478,955.
  • Characterisation of Melanoma Circulating Tumour Cells for Personalised Treatment,  Cancer Research Trust,  Postdoctoral Fellowship,  2014 - 2019,  $980,000.
  • Development of a Multiplex Test for the Early Diagnosis of Melanoma,  Tour de Cure,  Senior Research Grant,  2019,  $280,000.
  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab,  Merck Sharp and Dohme (Australia) Pty Ltd,  Grant,  2016 - 2019,  $73,300.
  • Single Cell Whole Transcriptome Sequencing of Melanoma Circulating Tumour Cells (CTCs): Unveiling Cell Diversity,  Tour de Cure,  Pioneering Cancer Research Grant,  2019,  $120,000.
  • Liquid Biopsy for Prognosis of Uveal Melanoma,  The Ophthalmic Research Institute of Australia,  ORIA - Grant,  2018,  $27,551.
  • Blood based biomarkers predictive of treatment efficacy in metastatic melanoma,  Spinnaker Health Research Foundation,  Collaborative Research Partnership Grants,  2017 - 2018,  $107,448.
  • Medical and Health Infrastructure Fund award 2016 Round 20,  Department of Health WA,  Medical and Health Research Infrastructure,  2017 - 2018,  $19,463.
  • Blood Based Biomarkers Predictive of Treatment Response in Melanoma,  Cancer Council of WA Inc,  Grant,  2016 - 2018,  $246,822.
  • A Blood Based ‘Liquid Biopsy’ to Improve Healthcare for Metastatic Melanoma Patients,  Department of Health WA,  SHRAC Research Translation Projects,  2016 - 2018,  $4,075,030.
  • Genetic Analysis of Blood Markers for Prognosis in Patients with Uveal Melanoma,  University of Western Australia,  Raine Foundation Grant,  2016 - 2018,  $100,000.
  • Circulating Tumour DNA to Predict and Monitor Treatment Response and Detect Acquired Resistance in Patients with Metastatic Melanoma,  Ramaciotti Foundation,  Grant,  2015 - 2018,  $99,911.
  • Understanding the Role of Melanoma Exosomes in Intercellular Communication,  Cancer Council of WA Inc,  Collaborative Cancer Grant Scheme,  2017 - 2018,  $43,230.
  • NHMRC Fellowship 'near-miss' funding,  Department of Health WA,  Near Miss Merit Awards,  2016 - 2017,  $50,000.
  • Circulating Melanoma Cells as Predictive Biomarkers of Treatment Response and Disease Status,  Cancer Council of WA Inc,  Grant,  2015 - 2017,  $111,519.
  • Using a Functional Protein Array to Identify Autoantibody Biomarkers with Diagnostic Potential for Melanoma,  National Health and Medical Research Council,  Development Grants,  2014 - 2017,  $778,368.
  • Western Australia Single-Cell Isolation and Genomics Preparation Facility,  Australian Research Council,  Grant - Linkage (Infrastructure),  2017,  $430,000.
  • New Independent Research Infrastructure Support Award 2016,  Department of Health WA,  New Independent Researcher Infrastructure Support (NIRIS) Awards,  2016 - 2017,  $10,000.
  • Gene expression profiling of circulating tumour cells (CTCs) isolated from metastatic melanoma patients using a microfluidic chip,  Cancer Council of WA Inc,  Grant - Early Career Investigator,  2016 - 2017,  $35,000.
  • Melanoma Mutation Profiling For Personalised Treatment,  National Health and Medical Research Council,  Project Grants,  2013 - 2016,  $765,359.
  • Circulating Tumour Cells (CTCs) as a diagnostic tool to monitor disease progression in melanoma patients,  Edith Cowan University,  ECU Industry Collaboration Grant - 2015 (Round 1),  2015 - 2016,  $137,227.
  • Mass Cytometry: A breakthrough in multidimensional systems biology,  Australian Research Council,  Grant - Linkage (Infrastructure),  2015 - 2016,  $1,081,489.
  • A Single-Molecule Super-Resolution Microscopy Facility in Western Australia,  Australian Research Council,  Grant - Linkage (Infrastructure),  2016,  $2,094,000.
  • Transcriptomic profiling of Circulating Tumour Cells (CTCs) isolated from metastatic melanoma patients,  Edith Cowan University,  School of Medical and Health Sciences Research Grant Scheme 2016,  2016,  $10,000.
  • Genetic Analysis of Melanoma Cells in Blood For Personalised Treatment Management,  Edith Cowan University,  ECU Early Career Researcher Grant - 2013,  2013 - 2014,  $24,083.
  • Detection of Vemurafenib Resistance in Circulating Tumour Cells for Personalised Treatment of Melanoma,  Harry Perkins Institute of Medical Research,  Scott Kirkbride Melanoma Research Centre - Discovery Research Priming Grant,  2013 - 2014,  $68,182.
  • Detection of stem cell markers expression in circulating melanoma cells using multiparameter flow cytometry as a prognosis tool,  Edith Cowan University,  ECU Early Career Researcher Grant - 2012 (Round 1),  2012 - 2013,  $19,480.
  • Expanding Capacity and Capability in Western Australian Flow Cytometry for Earth, Oceans, Environmental and Biomedical Science: State-of-the-Art Four Laser and 12 Colour Analysis,  Australian Research Council,  Grant - Linkage (Infrastructure),  2012 - 2013,  $598,000.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research,  National Health and Medical Research Council,  Equipment Grant 2011,  2011 - 2012,  $10,927.

Recent Publications (within the last five years)

Book Chapters

  • Freeman, J., Gray, E., Ziman, M., (2015), Circulating Tumor Cells as Biomarkers in Cancer. Biomarkers in Cancer, 31-51, London, UK, Springer, DOI: 10.1007/978-94-007-7681-4_21.

Journal Articles

  • Asante, D., Calapre, L., Ziman, M., Meniawy, T., Gray, E., (2019), Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, epub ahead of Print(October 11), In Press, DOI: 10.1016/j.canlet.2019.10.014.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M., (2019), Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(157), 15p., DOI: 10.3390/cancers11020157.
  • Gray, E., Witkowski, T., Pereira, M., Calapre, L., Herron, K., Irwin, D., Chapman, B., Khattak, M., Raleigh, J., Hatzimihalis, A., Cebon, J., Sandhu, S., McArthur, G., Millward, M., Ziman, M., Dubrovic, A., Wong, S., (2019), Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. The Journal of Molecular Diagnostics, 21(3), 418-426, DOI: 10.1016/j.jmoldx.2018.12.001.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, M., Millward, M., Meniawy, T., Gray, E., Ziman, M., (2019), Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122, DOI: 10.18632/oncotarget.26451.
  • Calapre, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, M., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E., (2019), Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2019), 171-184, United Kingdom, John Wiley & Sons Ltd, DOI: 10.1002/1878-0261.12391.
  • Armitage, J., Tan, D., Cha, L., Clark, M., Gray, E., Fuller, K., Moodley, Y., (2019), A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. Journal of Immunological Methods, 468(May 2019), 61-66, DOI: 10.1016/j.jim.2019.03.006.
  • Acheampong, E., Spencer, I., Lin, W., Ziman, M., Millward, M., Gray, E., (2019), Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 11(7), pii: E920, DOI: 10.3390/cancers11070920.
  • Khattak, M., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E., (2019), PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 24(2019), 1-8, DOI:
  • Calapre, L., Warburton, L., Millward, M., Gray, E., (2019), Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 19(2019), Article number 1109, United Kingdom, BioMed Central Ltd, DOI: 10.1186/s12885-019-6336-3.
  • Stark, M., Gray, E., Isaacs, T., Chen, F., Millward, M., McEvoy, A., Zaenker, P., Ziman, M., Soyer, H., Glasson, W., Warrier, S., Stark, A., Rolfe, O., Palmer, J., Hayward, N., (2019), A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 8(6), Article 12, DOI: 10.1167/tvst.8.6.12.
  • Beasley, A., Isaacs, T., Khattak, M., Freeman, J., Allcock, R., Chen, F., Pereira, M., Yau, K., Bentel, J., Vermeulen, T., Calapre, L., Millward, M., Ziman, M., Gray, E., (2018), Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2(May 17, 2018), 12p., United States, American Society of Clinical Oncology, DOI: 10.1200/PO.17.00279.
  • McEvoy, A., Wood, B., Ardakani, N., Pereira, M., Pearce, R., Cowell, L., Robinson, C., Grieu-Iacopetta, F., Spicer, A., Amanuel, B., Ziman, M., Gray, E., (2018), Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. The Journal of Molecular Diagnostics, 20(2), 240-252, United States, Elsevier, DOI: 10.1016/j.jmoldx.2017.11.009.
  • McEvoy, A., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M., Khattak, M., Meniawy, T., Millward, M., Ziman, M., Gray, E., (2018), Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), Article no. 726, United Kingdom, BioMed Central Ltd, DOI: 10.1186/s12885-018-4637-6.
  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P., (2018), Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036, DOI: 10.1038/s41598-018-36173-x.
  • Marsavela, G., Aya-Bonilla, C., Warkiani, M., Gray, E., Ziman, M., (2018), Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 424(Jun 2018), 1-8, Ireland, Elsevier, DOI: 10.1016/j.canlet.2018.03.013.
  • Zaenker, P., Lo, J., Pearce, R., Cantwell, P., Cowell, L., Lee, M., Quirk, C., Law, H., Gray, E., Ziman, M., (2018), A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 9(55), 30539-30551, United States, Impact Journals LLC, DOI: 10.18632/oncotarget.25669.
  • McEvoy, A., Calapre, L., Pereira, M., Giardina, T., Robinson, C., Khattak, M., Meniawy, T., Pritchard, A., Hayward, N., Amanuel, B., Millward, M., Ziman, M., Gray, E., (2017), Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 8(45), 78890-78900, Albany, United States, Impact Journals LLC, DOI: 10.18632/oncotarget.20354.
  • Calapre, L., Gray, E., Kurdykowski, S., David, A., Descargues, P., Ziman, M., (2017), SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 17(June 2017), Article No. 8, London, United Kingdom, BioMed Central, DOI: 10.1186/s12895-017-0060-y.
  • Aya-Bonilla, C., Marsavela, G., Freeman, J., Lomma, C., Frank, M., Khattak, M., Tarek, M., Millward, M., Warkiani, M., Gray, E., Ziman, M., (2017), Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 8(40), 67355-67368, New York, USA, Impact Journals LLC, DOI: 10.18632/oncotarget.18641.
  • Khattak, A., Gray, E., (2017), Ipilimumab Activity in Advanced Uveal Melanoma: A Pooled Analysis. International Journal of Cancer and Clinical Research, 4(2), article no.088, DOI: 10.23937/2378-3419/1410088.
  • Calapre, L., Warburton, L., Millward, M., Ziman, M., Gray, E., (2017), Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404(28 Sept, 2017), 62-69, Shannon, Ireland, Elsevier, DOI: 10.1016/j.canlet.2017.06.030.
  • Bradley, T., Trama, A., Tumba, N., Gray, E., Lu, X., Madani, N., Jahanbakhsh, F., Eaton, A., Xia, S., Parks, R., Lloyd, KE., Sutherland, LL., Scearce, RM., Bowman, CM., Barnett, SW., Abdool-Karim, SS., Boyd, SD., Melillo, BN., Smith III, AB., Sodroski, JG., Kepler, TB., Alam, SM., Gao, F., Bonsignori, M., Liao, H., Moody, MA., Montefiori, DC., Santra, S., Morris, L., Haynes, BF., (2016), Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 12(October), 196-207, Elsevier B.V., DOI: 10.1016/j.ebiom.2016.08.045.
  • Zaenker, P., Gray, E., Ziman, M., (2016), Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 15(5), 477-483, Elsevier, DOI: 10.1016/j.autrev.2016.01.017.
  • Calapre, L., Gray, E., Kurdykowski, S., David, A., Hart, P., Descargues, P., Ziman, M., (2016), Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 16(1), Article no. 6, London, UK, BioMed Central Ltd., DOI: 10.1186/s12895-016-0043-4.
  • Mufhandu, HT., Alexandre, KB., Gray, E., Morris, L., Khati, M., (2016), UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. Biochemistry and Biophysics Reports, 7(1), 408-414, Amsterdam, Netherlands, Elsevier B.V., DOI: 10.1016/j.bbrep.2016.07.005.
  • Bandawe, G., Moore, P., Werner, L., Gray, E., Sheward, D., Madiga, M., Nofemela, A., Thebus, R., Marais, J., Maboko, L., Karim, S., Hoelscher, M., Morris, L., Williamson, C., (2015), Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. Journal of Infectious Diseases, 211(9), 1461-1466, Oxford University Press, DOI: 10.1093/infdis/jiu633.
  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E., (2015), Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002, Philadelphia, USA, Elsevier, DOI: 10.1016/j.clinbiochem.2014.12.007.
  • Gray, E., Reid, A., Bowyer, S., Calapre, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M., (2015), Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048, London, United Kingdom, Nature Publishing Group, DOI: 10.1038/jid.2015.127.
  • Moody, A., Gao, F., Gurley, T., Amos, J., Kumar, A., Hora, B., Marshall, D., Whitesides, J., Xia, S., Parks, R., Lloyd, K., Hwang, K., Lu, X., Bonsignori, M., Finzi, A., Vandergrift, N., Alam, M., Ferrari, G., Shen, X., Tomaras, G., Kamanga, G., Cohen, M., Sam, N., Kapiga, S., Gray, E., Tumba, N., Morris, L., Zolla-Pazner, S., Gorny, M., Mascola, J., Hahn, B., Shaw, G., Sodroski, J., Liao, H., Montefiori, D., Hraber, P., Korber, B., Haynes, B., (2015), Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 18(3), 354-362, Cell Press, DOI: 10.1016/j.chom.2015.08.006.
  • Richardson, S., Gray, E., Mkhize, N., Sheward, D., Lambson, B., Wibmer, CK., Masson, L., Werner, L., Garrett, N., Passmore, J., Abdool Karim, Q., Abdool Karim, S., Williamson, C., Moore, P., Morris, L., (2015), South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on aα4β7 for replication. Retrovirology, 12(54), Article Number 54, DOI: 10.1186/s12977-015-0183-3.
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M., (2015), Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018, New York, USA, Impact Journals LLC, DOI: 10.18632/oncotarget.5788.
  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M., (2014), Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423, United Kingdom, BioMed Central Ltd, DOI: 10.1186/1471-2407-14-423.

Conference Publications

  • Maurya, D., Fooladvand, M., Gray, E., Ziman, M., Alameh, K., (2015), Lab-on-chip platform for circulating tumor cells isolation. Micro+Nano Materials, Devices, and Systems, 9668(6-9 Dec, 2015), 9668-34, Sydney, Australia, SPIE, DOI: 10.1117/12.2201127.

Research Student Supervision

Principal Supervisor


Associate Supervisor

  • Doctor of Philosophy: Addressing the impact of disasters on public health infrastructure and noncommunicable diseases
Skip to top of page